Compare ERO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | ARQT |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2021 | 2020 |
| Metric | ERO | ARQT |
|---|---|---|
| Price | $37.58 | $26.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 7 |
| Target Price | ★ $40.73 | $37.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $65.71 | $42.98 |
| Revenue Next Year | $9.87 | $27.75 |
| P/E Ratio | ★ $22.61 | $816.33 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $19.09 | $19.30 |
| 52 Week High | $40.83 | $31.77 |
| Indicator | ERO | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 54.80 |
| Support Level | $23.83 | $24.91 |
| Resistance Level | $40.00 | $28.20 |
| Average True Range (ATR) | 1.46 | 1.33 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 60.39 | 59.45 |
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.